IDEAS home Printed from https://ideas.repec.org/a/sae/medema/v23y2003i5p379-386.html
   My bibliography  Save this article

The Impact of Ignoring Population Heterogeneity when Markov Models are Used in Cost-Effectiveness Analysis

Author

Listed:
  • Gregory S. Zaric

Abstract

Many factors related to the spread and progression of diseases vary throughout a population. This heterogeneity is frequently ignored in cost-effectiveness analyses by using aver-age or representative values or by considering multiple risk groups. The author explores the impact that such simplifying assumptions may have on the results and interpretation of cost-effectiveness analyses when Markov models are used to calculate the costs and health impact of interventions. A discrete-time Markov model for a disease is defined, and 5 potential interventions are considered. Health benefits, costs, and incremental cost-effectiveness ratios are calculated for each intervention. It is assumed that the population is heterogeneous with respect to the probability of becoming sick. Ignoring this heterogeneity may lead to optimistic or pessimistic estimates of cost-effectiveness ratios, depending on the intervention and, in some cases, the parameter values. Implications are discussed of this finding on the use of league tables and on comparisons of cost-effectiveness ratios versus commonly accepted threshold values.

Suggested Citation

  • Gregory S. Zaric, 2003. "The Impact of Ignoring Population Heterogeneity when Markov Models are Used in Cost-Effectiveness Analysis," Medical Decision Making, , vol. 23(5), pages 379-386, September.
    • Handle: RePEc:sae:medema:v:23:y:2003:i:5:p:379-386
    DOI: 10.1177/0272989X03256883
    as

    Download full text from publisher

    File URL: https://journals.sagepub.com/doi/10.1177/0272989X03256883
    Download Restriction: no
    File URL: https://libkey.io/10.1177/0272989X03256883?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Kahn, J.G., 1996. "The cost-effectiveness of HIV prevention targeting: How much more bang for the buck?," American Journal of Public Health, American Public Health Association, vol. 86(12), pages 1709-1712.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Olivier Ethgen & Baudouin Standaert, 2012. "Population–versus Cohort–Based Modelling Approaches," PharmacoEconomics, Springer, vol. 30(3), pages 171-181, March.
    2. Gregory S. Zaric, 2008. "Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression," Health Economics, John Wiley & Sons, Ltd., vol. 17(11), pages 1277-1294, November.
    3. Oren Shavit & Moshe Leshno & Assaf Goldberger & Amir Shmueli & Amnon Hoffman, 2007. "It’s Time to Choose the Study Design!," PharmacoEconomics, Springer, vol. 25(11), pages 903-911, November.
    4. Grace Hui-Min Wu & Shu-Hui Chang & Tony Hsiu-Hsi Chen, 2008. "A Bayesian Random-Effects Markov Model for Tumor Progression in Women with a Family History of Breast Cancer," Biometrics, The International Biometric Society, vol. 64(4), pages 1231-1237, December.
    5. Gregory S. Zaric, 2008. "Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression," Health Economics, John Wiley & Sons, Ltd., vol. 17(11), pages 1277-1294.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. James G. Kahn & Margaret L. Brandeau & John Dunn-Mortimer, 1998. "OR Modeling and AIDS Policy: From Theory to Practice," Interfaces, INFORMS, vol. 28(3), pages 3-22, June.
    2. Brandeau, Margaret L. & Zaric, Gregory S. & Richter, Anke, 2003. "Resource allocation for control of infectious diseases in multiple independent populations: beyond cost-effectiveness analysis," Journal of Health Economics, Elsevier, vol. 22(4), pages 575-598, July.
    3. Gregory S. Zaric & Margaret L. Brandeau, 2001. "Optimal Investment in a Portfolio of HIV Prevention Programs," Medical Decision Making, , vol. 21(5), pages 391-408, October.
    4. Wilson, Amy R. & Kahn, James G. & Oren, Shmuel S., 2005. "Targeting interventions to high-risk populations: Benefits and costs," Socio-Economic Planning Sciences, Elsevier, vol. 39(4), pages 335-349, December.
    5. Lasry, Arielle & Zaric, Gregory S. & Carter, Michael W., 2007. "Multi-level resource allocation for HIV prevention: A model for developing countries," European Journal of Operational Research, Elsevier, vol. 180(2), pages 786-799, July.
    6. Robalino, David A. & Jenkins, Carol & El Maroufi, Karim, 2002. "Risks and macroeconomic impacts of HIV/AIDS in the Middle East and North Africa : why waiting to intervene can be costly," Policy Research Working Paper Series 2874, The World Bank.
    7. Stephanie R. Earnshaw & Anke Richter & Stephen W. Sorensen & Thomas J. Hoerger & Katherine A. Hicks & Michael Engelgau & Ted Thompson & K. M. Venkat Narayan & David F. Williamson & Edward Gregg & Ping, 2002. "Optimal Allocation of Resources across Four Interventions for Type 2 Diabetes," Medical Decision Making, , vol. 22(1_suppl), pages 80-91, September.
    8. Edward H. Kaplan, 1999. "Implicit Valuation of a Blood-exclusion Decision," Medical Decision Making, , vol. 19(2), pages 207-213, April.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:sae:medema:v:23:y:2003:i:5:p:379-386. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: SAGE Publications (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.